Wall Street Zen Downgrades Enovis (NYSE:ENOV) to Hold

Enovis (NYSE:ENOV) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other brokerages also recently weighed in on ENOV. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. William Blair started coverage on shares of Enovis in a report on Friday, April 17th. They set an “outperform” rating on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Enovis in a research report on Friday. Evercore set a $32.00 price objective on shares of Enovis in a research report on Monday, July 6th. Finally, Wells Fargo & Company reduced their target price on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a research note on Friday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Enovis Stock Up 0.3%

Shares of ENOV stock opened at $26.68 on Friday. Enovis has a 12 month low of $19.14 and a 12 month high of $34.28. The firm has a market cap of $1.54 billion, a PE ratio of -1.39 and a beta of 1.34. The stock has a 50 day moving average of $24.62 and a 200-day moving average of $23.97. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.Enovis’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis will post 3.12 EPS for the current year.

Insider Buying and Selling

In other news, insider Oliver Engert bought 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the transaction, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 4,200 shares of company stock valued at $92,084 over the last three months. 2.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently bought and sold shares of the business. Arax Advisory Partners acquired a new position in shares of Enovis in the 4th quarter valued at $29,000. EverSource Wealth Advisors LLC boosted its position in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares in the last quarter. Danske Bank A S acquired a new stake in shares of Enovis during the 3rd quarter valued at about $64,000. iSAM Funds UK Ltd acquired a new stake in shares of Enovis during the 3rd quarter valued at about $80,000. Finally, Brown Brothers Harriman & Co. acquired a new position in Enovis in the third quarter worth about $90,000. Institutional investors own 98.45% of the company’s stock.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.